Search Medical Condition
Please enter condition
Please choose location
 

Pico Rivera, California Clinical Trials

A listing of Pico Rivera, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (464) clinical trials

Clinical Trial Evaluating ITI-007 as a Monotherapy for the Treatment of Bipolar Depression

The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.

Phase

0.0 miles

Learn More »

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.

Phase

0.0 miles

Learn More »

Vortioxetine 5 10 and 20 mg Relapse Prevention Study in Adults With Major Depressive Disorder

The drug being tested in this study is called vortioxetine. Vortioxetine is being tested for the prevention of relapse in adults with major depressive disorder (MDD) who respond to daily treatment with vortioxetine. This study will look at relapse rates of MDD in people who take vortioxetine. The study will ...

Phase

0.62 miles

Learn More »

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.

Phase

0.62 miles

Learn More »

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.

Phase

0.62 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

This is a multicenter, randomized, double-blind, parallel-group, flexibly-dosed, study evaluating the efficacy and safety of SEP-363856 in acutely psychotic adult subjects with schizophrenia using SEP-363856 (50 or 75 mg/day [ie, once daily]) versus placebo over a 4-week treatment period. Primary hypoathesis to be tested: H0: μSEP = μPBO versus H1: ...

Phase

0.62 miles

Learn More »

An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)

This will be a randomized, placebo-controlled, parallel-group, multi-site, double-blind trial of MK-8189 compared with placebo, using Risperidone as an active control. The participants will be adult subjects experiencing an acute episode of schizophrenia, according to the criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5). ...

Phase

0.62 miles

Learn More »

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.

Phase

0.62 miles

Learn More »

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

This will be an open-label, uncontrolled study which will enroll completers from Study 31-08-250 and new subjects not participating in Studies 250. The treatment history of subjects prior to enrolment in the open-label study will vary according to the design of the pivotal double-blind study (i.e 31-08-250). This open-label study ...

Phase

0.62 miles

Learn More »

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease on Dialysis

This is a Phase 3, multicenter, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in dialysis patients. Patients on hemodialysis (HD) or peritoneal dialysis (PD) who have been treated with an erythropoietin analogue or have an indication ...

Phase

1.81 miles

Learn More »